Neurocrine Biosciences (NBIX) Other Non-Current Assets (2010 - 2026)

Neurocrine Biosciences has reported Other Non-Current Assets for 17 years, with the latest figure at $73.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 381.05% year-over-year to $73.6 million; the trailing twelve-month figure through Mar 2026 stood at $73.6 million (up 381.05% YoY), and the FY2025 full-year result was $59.5 million, up 14.42% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $73.6 million, up from $59.5 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $73.6 million in Q1 2026, with the low at $10.0 million in Q2 2022.
• Historically, Other Non-Current Assets has averaged $36.6 million across 5 years, with a median of $35.9 million in 2023.
• The largest YoY upside for Other Non-Current Assets was 468.18% in 2022 against a maximum downside of 97.16% in 2022.
• Neurocrine Biosciences' Other Non-Current Assets stood at $25.0 million in 2022, then jumped by 98.4% to $49.6 million in 2023, then climbed by 4.84% to $52.0 million in 2024, then advanced by 14.42% to $59.5 million in 2025, then grew by 23.7% to $73.6 million in 2026.
• The last three Other Non-Current Assets figures came in at $73.6 million (Q1 2026), $59.5 million (Q4 2025), and $20.3 million (Q3 2025), per Business Quant data.